{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.1","upperLimit":"12.9","value":"2.4"},{"groupId":"OG001","lowerLimit":"0.1","upperLimit":"13.2","value":"2.5"}]}],"title":"Week 44"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.5","upperLimit":"19.9","value":"7.3"},{"groupId":"OG001","lowerLimit":"0.1","upperLimit":"13.2","value":"2.5"}]}],"title":"Week 92"}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Elevation in SCr was defined as an increase greater than (\\>) 0.5 milligrams per deciliter (mg/dL) for participants with Baseline SCr less than (\\<) 1.4 mg/dL, or an increase \\>1.0 mg/dL for participants with Baseline SCr greater than or equal to (≥) 1.4 mg/dL. For the Week 44 analysis, the last available value on/before Week 44 was used. For the Week 92 analysis, the last available value on/before Week 92 was used. The percentage of participants with elevation of SCr at Weeks 44 and 92 was reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with multiple myeloma received ibandronate via 15-minute IV infusion as 6 mg every 4 weeks for up to 92 weeks. As a result of slow recruitment, the treatment duration was shortened to 40 weeks for participants who had not yet received 48 weeks of treatment. All participants returned for an additional follow-up observation 4 weeks after the end of treatment.","id":"OG000","title":"Ibandronate"},{"description":"Participants with multiple myeloma received zoledronate via 15-minute IV infusion as 4 mg every 4 weeks for up to 92 weeks. As a result of slow recruitment, the treatment duration was shortened to 40 weeks for participants who had not yet received 48 weeks of treatment. All participants returned for an additional follow-up observation 4 weeks after the end of treatment.","id":"OG001","title":"Zoledronate"}],"paramType":"NUMBER","populationDescription":"ITT Population.","reportingStatus":"POSTED","timeFrame":"Baseline and Weeks 44, 92","title":"Percentage of Participants With Elevation of Serum Creatinine (SCr) From Baseline","type":"SECONDARY","unitOfMeasure":"percentage of participants"}